Integrin beta-6: Its emerging role as a therapeutic target in solid tumors

Area of Science:

• Molecular Biology
• Oncology
• Immunology

Background:

• Integrins are transmembrane receptors mediating cell communication.
• Integrin beta-6 (IB6) is upregulated in epithelial remodeling and tumorigenesis.
• IB6 promotes cancer cell migration, invasion, proliferation, and survival.

Purpose of the Study:

• To evaluate IB6 as a therapeutic target in cancer.
• To assess the efficacy of IB6-targeting antibody-drug conjugates (ADCs).

Main Methods:

• Preclinical investigations of various IB6-targeting strategies.
• Clinical evaluation of Sigvotatug vedotin, an IB6-ADC, in advanced solid tumors.
• Ongoing Phase 3 studies for Sigvotatug vedotin.

Main Results:

• Early IB6-targeting strategies showed limited clinical success.
• Sigvotatug vedotin demonstrated promising efficacy in a Phase 1 study for advanced solid tumors, especially non-small cell lung cancer.
• Other IB6-ADCs exhibit antitumor activity in preclinical studies and are entering clinical development.

Conclusions:

• IB6 is a promising therapeutic target for anticancer strategies.
• IB6-directed ADCs, like Sigvotatug vedotin, represent a viable and effective approach.
• Further research will clarify IB6's role as a therapeutic target and biomarker.